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Highlights
 Assessment of MRI parameters in a single scan session.
 Higher liver T1 and reduced liver perfusion with increasing
disease severity and clinical outcomes.
 Reduced renal cortex T1 linked to disease severity and
clinical outcomes.Christopher R. Bradley, Eleanor F. Cox,
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This study assesses the changes to struc-
ture, blood flow and perfusion that occur
in the key organs (liver, spleen and kid-
ney) associated with severe liver disease
(Compensated Cirrhosis), using magnetic
resonance imaging. The magnetic reso-
nance imaging measures which changed
with disease severity and were related to
negative liver-related clinical outcomes
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Background & Aims: Advancing liver disease results in delete-
rious changes in a number of critical organs. The ability to
measure structure, blood flow and tissue perfusion within
multiple organs in a single scan has implications for determin-
ing the balance of benefit vs. harm for therapies. Our aim was
to establish the feasibility of magnetic resonance imaging
(MRI) to assess changes in Compensated Cirrhosis (CC), and
relate this to disease severity and future liver-related out-
comes (LROs).
Methods: A total of 60 patients with CC, 40 healthy volunteers
and 7 patients with decompensated cirrhosis were recruited.
In a single scan session, MRI measures comprised phase-
contrast MRI vessel blood flow, arterial spin labelling tissue per-
fusion, T1 longitudinal relaxation time, heart rate, cardiac index,
and volume assessment of the liver, spleen and kidneys. We
explored the association between MRI parameters and disease
severity, analysing differences in baseline MRI parameters in
the 11 (18%) patients with CC who experienced future LROs.
Results: In the liver, compositional changes were reflected by
increased T1 in progressive disease (p <0.001) and an increase
in liver volume in CC (p = 0.006), with associated progressive
reduction in liver (p <0.001) and splenic (p <0.001) perfusion.
A significant reduction in renal cortex T1 and increase in cardiac
index and superior mesenteric arterial blood flow was seen with
increasing disease severity. Baseline liver T1 (p = 0.01), liver per-
fusion (p <0.01), and renal cortex T1 (p <0.01) were significantly
different in patients with CC who subsequently developed neg-
ative LROs.
Conclusions:MRI enables the contemporaneous assessment of
organs in liver cirrhosis in a single scan without the require-
ment for a contrast agent. MRI parameters of liver T1, renal T1,
hepatic and splenic perfusion, and superior mesenteric arterial
blood flow were related to the risk of LROs.
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Lay summary: This study assesses the changes to structure,
blood flow and perfusion that occur in the key organs (liver,
spleen and kidney) associated with severe liver disease
(Compensated Cirrhosis), using magnetic resonance imaging.
The magnetic resonance imaging measures which changed with
disease severity and were related to negative liver-related
clinical outcomes are described.
 2018 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The evolution of liver cirrhosis to clinical liver-related outcomes
resulting from portal hypertension is not simply dictated by
architectural and haemodynamic changes within the liver.
Rather, advancing liver disease results in deleterious changes
in a number of critical organs and the understanding of this pro-
cess is a central aspect in the clinical management of cirrhotic
patients.
The hyperdynamic circulation in cirrhosis is characterised by
increased cardiac output and decreased systemic vascular resis-
tance with low arterial blood pressure.1–3 Splanchnic vasodila-
tion, with a resulting decrease in the effective central volume,
has been proposed as an important driver of the hyperdynamic
circulation.1,4 Associated with splanchnic vasodilation is an
increase in portal vein blood flow which maintains and perpet-
uates portal hypertension.5 Further, architectural and haemody-
namic changes in the heart, spleen, and kidney have also been
shown to occur and have important pathophysiological conse-
quences. For example, cirrhotic cardiomyopathy is characterised
by increased cardiac output with a sub-optimal ventricular
response to stress, and structural and electrophysiological
abnormalities.2 Cardiac dysfunction associated with cirrhosis
has been shown to be an important prognostic determinant of
mortality at one year.6 Renal vasoconstriction, related to
splanchnic vasodilation, portal hypertension and activation of
compensatory neurohormonal systems, is a precursor for the
development of hepatorenal syndrome.3,6,7 In cirrhosis, splenic
enlargement may result from portal venous congestions and/
or hyperplasia. In association, the splenic artery is suggested
to dilate,8 and recent data suggests that the splenic artery to
hepatic artery diameter ratio can predict the development of018 vol. 69 j 1015–1024
Research Article Cirrhosisascites and varices.9 Splenic stiffness has also been found to
have a strong association with portal hypertension.10,11 How-
ever, there is an incomplete understanding of how changes in
the different organs are inter-related, and what temporal
relationships exist.
The importance of assessing critical organs in liver cirrhosis
in a holistic fashion is illustrated by the current controversy sur-
rounding beta-blockers in liver cirrhosis. The debate regarding
the safety of beta-blockers focusses on whether the beneficial
effects of beta-blockers in liver cirrhosis, centred around a
reduction in cardiac output, splanchnic vasodilation and portal
inflow and improvement in intrahepatic resistance (alpha 1
blockade), is counterbalanced by deleterious effects in advanced
cirrhosis centred on a reduction in renal perfusion and cardiac
output as described previously.12 A key limitation in being able
to define the critical window6,13 of benefit of beta-blockers vs.
harm is the lack of robust non-invasive tools to measure
changes across organs in a contemporaneous manner. If this
could be done, treatment could be individualised more effec-
tively. This does not currently occur in clinical practice, in a con-
sistent manner, as the tools for measurement are blunt (e.g.
heart rate) or invasive (hepatic venous pressure gradient mea-
surement [HVPG]).
Recent advances in non-invasive magnetic resonance imag-
ing (MRI) techniques allow the assessment of blood flow to
organs,14 tissue perfusion,15,16 and compositional changes
including fibrosis and inflammation,17–19 in the key organs
associated with cirrhosis. Until now, such measures have only
been examined in single organs rather than using a comprehen-
sive multi-organ approach in a single scan session.
Our aim was to assess the feasibility of performing MRI to
contemporaneously analyse the liver, heart, spleen and kidneys
in patients with Compensated Cirrhosis (CC). We aim to
describe the differences in quantitative MRI measures within
these organs between healthy volunteers, and patients with
CC and Decompensated Cirrhosis (DC). As proof of concept, we
explore whether differences in MRI parameters are observed
in patients with future clinical liver-related outcomes.
Materials and methods
Study population
Sixty patients were consecutively recruited from a CC cohort
study, a prospective study initiated in 2010 focussed on tracking
liver disease progression. Here, baseline measures collected for
this cohort are reported. Institutional and local research
approval was gained (10/H0403/10). Patients were recruited
with evidence of cirrhosis (confirmed by a combination of
biopsy, clinical and radiological criteria) and no evidence of
decompensation (ascites, significant jaundice, hepatic
encephalopathy and variceal bleeding), hepatocellular carci-
noma and portal vein thrombosis. Exclusion criteria included
orthotopic liver transplantation, ischaemic heart disease, alco-
holic cardiomyopathy (defined by clinical evidence of systolic
dysfunction) and valvular heart disease.
For comparator measures, we prospectively recruited two
additional groups – a Healthy Volunteer (HV) and Decompen-
sated Cirrhosis (DC) group. Forty HVs were recruited who had
no major co-morbidity including cardiovascular or chronic liver
disease. Seven ambulatory patients with DC were recruited,
defined as Baveno 3 or 4 stage (ascites, encephalopathy or pre-
vious variceal bleed); exclusion criteria included portal vein1016 Journal of Hepatology 20thrombosis, the presence of hepatocellular carcinoma (HCC),
and orthotopic liver transplantation. Subjects attended on a sin-
gle study day following an overnight fast. Statistical power to
assess the difference between groups was determined for each
MRI parameter at a power of 80% and significance level of 5%.
Patients were invited to return for research visits on a six-
monthly basis for assessment of liver-related clinical outcomes
as defined by ascites (needing paracentesis or diuretic therapy),
grade 3 or grade 4 encephalopathy, variceal haemorrhage
requiring endoscopic therapy and emergency admission, HCC
(defined by EASL criteria) and liver-related death. For patients
who declined follow-up visits, we obtained their consent to
access relevant medical records (both family practitioner and
hospital records) to record clinical outcomes.
Multi-organ MRI protocol
All participants were scanned following a 6 h fast, with MRI
scans carried out between 8 am–12 pm. Imaging was performed
on a 1.5 T Philips Achieva MRI scanner (Best, Netherlands) using
a 16-element Torso receive coil and body transmit coil. MR
measures were collected on four organs: liver – blood flow in
the portal vein and hepatic artery, liver perfusion and tissue
T1; spleen and superior mesenteric artery (SMA) – blood flow
assessed in the splenic and SMA, splenic tissue perfusion and
tissue T1; renal – blood flow in right renal artery, kidney vol-
ume, renal tissue perfusion and tissue T1; heart – aortic blood
flow corrected for body surface area (BSA) to yield cardiac index
and left ventricular (LV) wall mass as a measure of cardiac
strain. This non-invasive protocol took less than 1 h for hepatic
(20 min), spleen, SMA and renal (15 min), and cardiac (10
min) measures. The following describes the acquisition protocol
parameters.
Organ volume
First multi-slice balanced turbo-field echo (bTFE) localiser
images were acquired in three perpendicular orientations to
locate organs and vessels of interest for slice positioning, and
from which to estimate organ (liver, kidney and spleen) volume.
Blood flow measures
Phase-contrast (PC)-MRI was used to quantify vessel lumen
cross-sectional area (CSA), velocity and bulk blood flow in ves-
sels within each system. A TFE technique (two averages, TFE fac-
tor 4–6 dependent on subjects’ heart rate) was used with a
single slice perpendicular to the vessel of interest. A total of
15 phases were collected across the cardiac cycle using specified
velocity encoding for each vessel (portal vein 50 cm/s, hepatic/
splenic/renal arteries 100 cm/s, SMA 140 cm/s). Each vessel
measurement was acquired during a 15–20 s breath hold.
Perfusion of the liver, spleen and kidney
Respiratory-triggered Flow Alternating Inversion-Recovery
Arterial Spin Labelling (FAIR-ASL)15,16 (post-labelling delay
1,100 ms, balanced fast field echo [bFFE] readout) was used to
measure tissue perfusion in the liver, spleen and renal tissue.
Liver perfusion data was acquired in three sagittal slices
through the right lobe (slice gap 5 mm, 60 ASL pairs in 8
min), spleen/renal perfusion data was collected in five contigu-
ous coronal-oblique slices through the spleen and long axis of
the kidney (30 ASL pairs in 5 mins). An equilibrium base mag-
netisation M0 and T1 image was acquired for each slice orienta-
tion for perfusion quantification.18 vol. 69 j 1015–1024
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A modified respiratory-triggered inversion-recovery
sequence16,19,20 was used to measure tissue T1 in the liver,
spleen and kidney, with slices geometrically matched to the
ASL data. For liver tissue, a fat suppressed spin-echo
echo-planar imaging (SE-EPI) readout was used to ensure no
influence of fat on T1 measures. Data was collected at 13 inver-
sion times (TI) (100–1,200 ms in 100 ms steps, and 1,500 ms)
with minimal temporal slice spacing between the three
slices (65 ms) collected in a descend slice order, in an acquisi-
tion time of 2 min. For the spleen and kidney, a bFFE readout
was used and data acquired at 9 TIs (100–900 ms in 100 ms
steps) with minimal temporal slice spacing (144 ms), both
ascend and descend slice order acquisitions were acquired to
increase the dynamic range of inversion times16,19,20 in 3
min. It was confirmed that study participants did not have
excess iron.16,19,20
Cardiac assessment
Cardiac output was measured using a PC-MRI of the aorta with
30 phases and velocity encoding of 200 cm/s in 1 min whilst
free breathing. Short-axis cine images were acquired to measure
LV wall mass using a multi-slice TFE sequence (12 slices, 30
phases, 3 slices acquired per 15–20 s breath hold).
Data analysis
Blood flow measures
‘Q-flow’ software (Philips Medical Systems) was used to analyse
PC-MRI data. For each vessel, a region-of-interest (ROI) was
drawn to estimate flow by averaging the flow velocity values
within the ROI and multiplying by vessel lumen CSA. Mean flow
was calculated by averaging the flow rates for each cardiac
phase across the cardiac cycle.
Perfusion
The analysis procedure for ASL data performed using MATLAB
and/or IDL routines is shown (Fig. S1). Each ASL label/control
image was motion corrected to the base magnetisation M0
image using in-house software. Individual perfusion-weighted
images (control-label) were calculated, inspected for motion
(exclude >1 voxel movement) and averaged to create a single
perfusion-weighted image (DM). DM, M0 and T1 maps were
used in a kinetic model21 to compute tissue perfusion maps. A
binary mask of each organ (see relaxometry section) was formed
and used to calculate the mean liver, spleen and renal cortex
perfusion.
Relaxometry
Inversion-recovery data were fit to a two-parameter model
to generate T1 and M0 maps. Binary organ masks were
formed from the M0 image, and major blood vessels further seg-
mented by excluding voxels with a T1 >1,500 ms. Median T1 val-
ues were calculated within liver and spleen masks. For the
kidney mask, a histogram of T1 values was formed to yield
two peaks originating from the renal cortex and medulla
(Fig. S1A), and the median T1 values of the renal cortex and
medulla calculated.
Volume
Analyze (Mayo Clinic) was used to draw an ROI around each
organ (liver, kidney, spleen) within each slice, and total organ
volume calculated by summing across slices.
Journal of Hepatology 20Cardiac
Cardiac MRI data was analysed using ViewForum software (Phi-
lips Medical Systems, Best, Netherlands). PC-MRI data of the
aorta was analysed by computing the stroke volume and heart
rate, and multiplying these parameters to yield cardiac output.
This software was also used to draw wall contours from which
LV wall mass was calculated. Both cardiac output and LV wall
mass are presented corrected for BSA.22
Validation of MR measures
T1 relaxometry of the liver
We assessed liver histology in a cohort of patients with cirrhosis
who previously had T1 mapping of the liver on a 1.5 T scan,19,20
all MRI scans were collected within three months of liver
biopsy. Liver biopsies were obtained via either the percutaneous
or the transjugular route from patients with METAVIR fibrosis
stage 4. Patients were fasted overnight before the procedure
and biopsies were carried out by experienced operators. Biop-
sies were stained with hematoxylin and eosin, picrosirius red
(PSR) and Perls’ Prussian blue stains. All biopsy data were anal-
ysed by a single experienced pathologist blinded to MRI data.
The percentage of fibrous tissue relative to the total biopsy area
was estimated for each biopsy by visual morphometry.17 A
Spearman’s rank correlation coefficient (in terms of R value)
was computed between the continuous variables of visual mor-
phometry and liver tissue T1.
All patients with CC had a blood sample to assess non-
invasive markers of liver fibrosis (Enhanced Liver Fibrosis
[ELF] score). In addition, in all patients with CC, transient elas-
tography evaluation was performed using FibroScan (Echo-
Sens, Paris, France) to provide a liver stiffness measure (LSM)
in kPa. The FibroScanmeasure was repeated to obtain 10 read-
ings and a median LSM value calculated. Spearman’s rank corre-
lation coefficients (R value) are presented between ELF and LSM
with a statistical significance threshold of p < 0.05.
ASL perfusion of the liver
In all patients, measures of indocyanine green (ICG) were per-
formed and plasma disappearance rate (ICG-PDR, percentage
of ICG eliminated in 1 min after an ICG bolus) (%/min), and its
retention rate at 15 min (ICGR15, the circulatory retention of
ICG during the first 15 min after a bolus injection (%)) com-
puted. A Spearman’s rank correlation coefficient was performed
between ICG-PDR and ICGR15 and liver perfusion as measured
using arterial spin labelling. Correlation coefficients are pre-
sented in terms of R value with a statistical significance thresh-
old of p < 0.05.
Repeatability of multiparametric MRI measures
To determine the between session repeatability of MRI mea-
sures, the intra-subject Coefficient of Variation (CoV) (defined
as the standard deviation/mean) of multiparametric MRI mea-
sures were assessed. A subset of 10 healthy participants (age
23–37 years, body mass index 20–26 kg/m2) had three scans,
at least one week apart and within four weeks, at the same time
of day and after an overnight fast to limit diurnal and dietary
variability. The CoV measures are provided (Table S1).
Statistical analysis
All statistical analysis was performed using Prism 6 (GraphPad
Software, Inc., La Jolla, CA). A Shapiro-Wilk normality test was
applied to data collected on each MRI parameter. Normal data
18 vol. 69 j 1015–1024 1017
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(interquartile range, IQR) across each group. Tests between
the three patient groups were made using a one-way analysis
of variance (one-way ANOVA) with Bonferroni correction for
normally distributed data, otherwise a Kruskal-Wallis test was
performed to assess probable differences between the groups,
with post hoc Tukey’s test where significant differences were
identified.
To compare results between patients with CC who did or did
not have a negative liver-related clinical outcome, a two-tailed
unpaired t test was performed to assess differences in normally
distributed parameters, or a Mann-Whitney U test was per-
formed, significance was considered at p < 0.05. In addition, to
test the probability of organ involvement in outcome, a survival
analysis was performed providing Kaplan-Meier curves and sig-
nificance of difference determined by a log-rank test, using the
1st tertile of MRI parameters as cut-off values.
For further details regarding the materials used, please refer
to the CTAT table.Results
The CC cohort (n = 60) comprised 25 females and 35 males, aged
60 ± 9 years, with a range of aetiologies, the largest being Alco-
holic Liver Disease (ALD, 21 patients, 35%), Non-Alcoholic Fatty
Liver Disease (NAFLD, 16 patients, 27%), and Hepatitis C Virus
(HCV, 12 patients, 20%), with the remaining 18% of patients hav-
ing primary biliary cirrhosis, Hepatitis B Virus (HBV), primary
sclerosing cholangitis, autoimmune hepatitis and haemochro-
matosis. Mean model for end-stage liver disease (MELD) score,
FIB4 and aspartate aminotransferase-to-platelet ratio index
(APRI) scores were 7.7 ± 2.1, 3.4 ± 2.3, and 1.2 ± 1.2. Of this
group, six patients were on beta-blockers. The healthy volunteer
(HV) group (n = 40) comprised 17 female and 23 male patients,
aged 59 ± 10 years. The DC (n = 7) group comprised five female
and two male patients of 48 ± 13 years, five of whom had ALD,
one NAFLD and one HCV, with decompensation type comprising
four cases of ascites, two of varices and one encephalopathy.
Mean MELD, FIB4 and APRI scores were 9.9 ± 3.3, 3.5 ± 1.6,






































































Fig. 1. Changes in the liver in Healthy Volunteers, patients with Compensate
one-way ANOVA, followed by the Tukey post hoc test. *p < 0.05, **p < 0.01, ***p <
Decompensated Cirrhosis; HV, healthy volunteers.
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T1 relaxometry of the liver
T1 relaxation time correlated significantly with visual
morphometry of percentage fibrosis in advanced F4 fibrosis
(R = 0.62, p < 0.001) (Fig. S2). As a secondary outcome, we show
a significant positive correlation of liver tissue T1 with ELF score,
R = 0.65 and p < 0.001 (Fig. S3). In addition, a highly significant
correlation of liver tissue T1 with the LSM from FibroScan

was demonstrated (R = 0.68, p < 0.001) (Fig. S3).
ASL perfusion of the liver
In all patients ICG measures were collected and correlated with
liver perfusion as measured by ASL. A weak but significant pos-
itive correlation was demonstrated between liver perfusion
measured using ASL and ICG-PDR (R = 0.46, p = 0.0016), and
negative correlation with ICGR15 (R = 0.46, p = 0.0011) (Fig. S4).
Repeatability of multiparametric MRI measures
Intra-subject repeatability for all the multiparametric MRI mea-
sures is provided (Table S1). Measurement of MR parameters is
highly repeatable with a CoV of <10% in assessment of volume,
T1 relaxometry measures, and ASL perfusion.
Changes in compensated and decompensated cirrhosis
compared to healthy volunteers
In the following section, MRI measures are provided for each
organ studied – liver, spleen and SMA, renal and cardiac – and
compared across the stages of disease severity, i.e. HV vs. CC
vs. DC.
Liver
The changes measured in the liver across the three groups are
shown (Fig. 1). Liver volume was significantly greater in
patients with CC compared to both HVs and those with DC (p
= 0.006). We observed liver tissue T1 progressively increased
with disease severity, from HV to CC and DC (p < 0.001), with
statistically significant differences between the HV and CC
group (p < 0.001), and the CC and DC group (p = 0.01). Portal
vein CSA significantly increased in CC patients compared to

























































































d Cirrhosis and those with Decompensated Cirrhosis. Data analysed using
0.005, ****p < 0.001. CC, Compensated Cirrhosis; CSA, cross-sectional area; DC,
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disease severity (though not significant p = 0.09). Total hepatic
blood flow (portal vein + hepatic artery flow) significantly
increased with disease severity (p = 0.03). The percentage con-
tribution of portal vein flow to total hepatic flow (portal vein
flow + hepatic artery flow) did not significantly change with
liver disease severity (77.9 ± 1.2%, 72.8 ± 1.9%, and 74.5 ± 6.7%
for HV, CC, and DC respectively). Liver perfusion significantly
reduced with disease severity (p < 0.001), with statistically sig-
nificant differences between the HV and CC group (p < 0.001),
and the CC and DC groups (p < 0.01).
Spleen and SMA
Changes in the spleen and SMA across the groups are shown
tissue perfusion significantly decreased with disease severity
(p < 0.001, 151 ± 7 ml/100 g/min, 120 ± 6 ml/100 g/min, and
82 ± 9 ml/100 g/min for HV, CC, and DC respectively).
Renal
Renal changes across the groups are shown (Fig. 3). No signifi-
cant difference is seen in total renal volume between the HV,
CC and DC groups. A significant reduction in renal cortex T1
(p < 0.001) was demonstrated with disease severity, a trend
for reduced T1 was found in the renal medulla but this was
not significant. No significant difference was found in CSA of
the renal artery or renal artery bulk flow, but flow per beat
reduced with disease severity. No significant difference in renal
JOURNAL 
OF HEPATOLOGY(Fig. 2). Spleen volume was increased in the CC and DC groups
compared to HVs (p < 0.03; 206 ± 16 ml, 459 ± 34 ml, and
490 ± 112 ml for HV, CC, and DC respectively), with spleen T1
increasing with disease severity. No significant difference was
found in CSA of the splenic artery, whilst splenic artery bulk
flow significantly increased with disease severity (p < 0.001).




















































































Fig. 2. Changes in the spleen and superior mesenteric artery in Healt
Decompensated Cirrhosis. Data analysed using one-way ANOVA, followed by













































































Fig. 3. Changes in the kidney in healthy volunteers, patients with Compensa
one-way ANOVA, followed by the Tukey post hoc test. *p < 0.05, **p < 0.01, ***p <
Decompensated Cirrhosis; HV, Healthy Volunteers.
Journal of Hepatology 20cortex perfusion was found between the HV, CC, and DC groups.
Cardiac
Differences in cardiac parameters across the groups are shown
(Fig. 4). Cardiac index significantly increased with disease sever-
ity (p = 0.005). This was driven by the increase in heart rate with
































































hy Volunteers, patients with Compensated Cirrhosis and those with
the Tukey post hoc test. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. CC,















































ted Cirrhosis and those with Decompensated Cirrhosis. Data analysed using
0.005, ****p < 0.001. CC, Compensated Cirrhosis; CSA, cross-sectional area; DC,
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per minute (bpm) for HV, CC, and DC, respectively), no signifi-
cant change in stroke volume was found with disease severity.
BSA corrected cardiac LV wall mass was significantly different
across the groups (p = 0.02; 39.0 ± 1.1, 34.0 ± 1.7, 22.3 ± 2.4
g/m2 for HV, CC, and DC respectively).
Assessment of baseline MR parameters related to a future
clinical outcome in patients with compensated cirrhosis at
baseline
Here, we present baseline MRI data for those patients with CC
who developed a liver-related outcome. Of the 60 patients with
CC at baseline (mean MELD score 7.7), 11 patients (18%) devel-
oped a future liver-related outcome. The median number of















































p = 0. 0
Fig. 4. Changes in the cardiac function between healthy volunteers, patients w
analysed using one-way ANOVA, followed by the Tukey post hoc test. *p <
Decompensated Cirrhosis; HV, Healthy Volunteers.
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Outcome No outcome Outcome No outcome Outco
Outcome No outcome Outcome No outcome Outc
Fig. 5. Baseline MRI parameters in patients with Compensated Cirrhosis, wit
platelet ratio index; CC, Compensated Cirrhosis; FIB4, fibrosis 4 score; MELD, m
analysis performed using two-tailed unpaired t-test.




















ith Compensated Cirrhosis and those with Decompensated Cirrhosis. Data
0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. CC, Compensated Cirrhosis; DC,(range: 59–2,304). Seven had ascites, one developed
encephalopathy, one developed a variceal bleed, two had HCC.
Of these patients, seven patients died of a liver-related cause
after the first liver-related outcome; liver failure (four cases)
and HCC (three cases) as listed on the death certificate.
The patients with an outcome were aged 59 ± 6 years, six
were male and five female, with aetiologies including four with
HCV, five with ALD, one with NAFLD and one with HBV. How the
MR parameters found to be significantly different between HVs,
CC and DC patients relate to clinical liver-related outcomes is
displayed (Fig. 5).
There was no significant difference in liver volume between
patients with CC with and without a liver-related outcome. In
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h and without liver-related outcomes. APRI, aspartate aminotransferase-to-
odel for end-stage liver disease; SMA, superior mesenteric arterial. Statistical












OF HEPATOLOGYthose patients with CC and a clinical outcome (834 ± 36 ms)
compared to those without (719 ± 10 ms). The CSA of the portal
vein was not significantly different between patients with CC,
with and without a clinical outcome. Total hepatic blood flow
was significantly (p = 0.05) lower in those with outcomes (13.
4 ± 7.6 ml/s) compared to those patients with no outcomes
(17.8 ± 6.0 ml/s). Perfusion measured in the right lobe of the
liver was significantly lower (p < 0.01) in those patients with
an outcome (clinical liver-related outcome: 95.8 ± 9.5 ml/100 g
/min, no liver-related outcome: 160 ± 8.0 ml/100 g/min).
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Days after MR scan to outcome 
Fig. 6. Kaplan-Meier curves for liver-related outcome survival in patients
with Compensated Cirrhosis. (A) There were significant differences between
those with Liver T1 for the 1st tertile T1 of 793 ms (p < 0.001). (B) There was
significance between liver perfusion using the 1st tertile of 125 ml/100 g/min
(p < 0.001). (C) There was a significant difference between renal T1 using a 1st







Fig. 7. Multi-organ changes demonstrated in this study in compensated an
in key organs (heart, liver, splanchnic and kidney) demonstrated in this study o
A hyperdynamic circulation results in increased blood flow in the liver, splanc
increases in spleen blood flow and cardiac index in patients with DC. Here liver
the HV group, and perfusion in these organs is further reduced in those with D
and DC, and the HV group. Liver tissue T1 increased in patients with CC co
significantly different from the HV group in DC patients. In contrast renal T1 wa
HVs. LV wall mass was significantly reduced in patients with DC compared to
spleen volume was increased in patients with CC and DC compared to HVs. CC,Journal of Hepatology 20No significant difference was found in spleen volume or splenic
T1 between those with and without outcomes, but splenic per-
fusion was lower and SMA blood flow higher in those with a
clinical outcome. Renal cortex T1 was significantly shorter in
the patients with CC and an outcome (919 ± 28 ms) compared
to those with no outcome (1,012 ± 11 ms). There was no signif-
icant difference in cardiac measures of cardiac index or LV wall
mass index between those with and without a clinical outcome.
Tertile cut-off points (as used in23) of liver perfusion, liver T1
and renal T1 were used to compute Kaplan-Meier survival
curves (Fig. 6). These MRI parameters were significant predic-
tors of liver-related outcomes.
Discussion
We have shown that it is feasible to study changes in cirrhosis
representing the flow, volume, composition and perfusion in
critical organs (liver, kidney, spleen and heart) in a contempora-
neous fashion in a single scan session using quantitative MRI
without requiring the injection of a contrast agent. Individual
MR components change with disease severity, as illustrated by
Fig. 7, and taken together this data provides a comprehensive
evaluation of cirrhosis relating to aspects of structure and
haemodynamics. Furthermore, a subset of MRI markers mea-
sured at baseline (i.e. liver T1, liver perfusion and renal cortex
T1) differentiate two groups of patients with CC, those who
develop or do not develop a future liver-related clinical outcome
up to seven years later (Figs. 5, 6).
This study highlights two conceptual aspects that are coher-
ent with our current understanding of how liver disease pro-
gresses. Firstly, structural changes as evidenced by changes in
organ volume (i.e. spleen and liver) and compositional change
(i.e. increased liver T1 and splenic T1) relate to increasing disease
progression from the spectrum of HVs to DC. Secondly, changes
in haemodynamics, both to and within the organ, evolve with
progressive disease. This is exemplified by the reduction in both
liver and splenic perfusion. Despite the small size of the DC
group, it is interesting to note that the reduction of hepatic per-
fusion occurs in the context of increased total hepatic blood
delivery in the CC and DC group, though this only results in
Decompensated 
cirrhosisssue Volume Flow Perfusion Tissue Volume
decompensated liver disease. Infographic to pictorially illustrate the changes
ontemporaneous MR measures in compensated and decompensated cirrhosis.
nic circulation and increased cardiac output in patients with CC, with further
d splenic perfusion was shown to be reduced in patients with CC compared to
No significant change in renal perfusion was found between patients with CC
pared to HVs, and further increased in those with DC. Spleen T1 was only
educed in patients with CC and further reduced in those with DC, compared to
Vs, whilst liver volume was found to increase only in patients with CC, and
ompensated Cirrhosis; DC, Decompensated Cirrhosis; HV, Healthy Volunteers.18 vol. 69 j 1015–1024 1021
the liver (prolonged liver T1 values, Fig. 1) and haemodynamic
changes in the liver (reduced liver perfusion, Fig. 1), there is a
sible that acute insults, including sepsis, that lead to hospitalisa-
tion tip the balance of these compensatory mechanisms.
data supports this concept of differential visceral blood flow
in cirrhosis.
ment of MRI protocols for liver blood flow would be beneficial.
as such this invasive procedure is far less practical. Doppler
ultrasound has been widely used to assess blood flow in liver
doppler beam angle and operator experience. Annet et al.
showed PC-MRI parameters have the sensitivity to detect a sig-
Research Article Cirrhosisan increase in normalised hepatic blood flow between the HV
and DC group (Fig. S5). The reduction in liver volume that occurs
in DC compared to CC patients, as previously shown in,24 sug-
gests that this is not related to a larger mass of liver tissue to
supply. We hypothesise two explanations for this discordance.
Firstly, intrahepatic shunting may occur, although using our
current MR methods we do not have the spatial resolution to
directly visualise shunts. Secondly, in liver disease it is difficult
to use normalised hepatic blood flow as a measure of global per-
fusion due to the underlying changes in liver composition. The
deposition of fat, interstitial oedema and inflammatory cells
can all potentially increase liver volume. As the liver starts
decompensating, these features subside and in addition there
is a loss of hepatocyte volume relative to an increasing amount
of extracellular matrix.25 This highlights the importance of mea-
suring perfusion rather than blood flow per se.
The increase in splenic artery blood flow is largely compen-
sated for by the increase in spleen volume, with a trend for a
reduction in normalised splenic flow (Fig. S5) in agreement with
the significant reduction in perfusion. The increase in splenic T1
also suggests that angio-architectural changes occur within the
spleen, perhaps related to fibrosis. Finally, there was a trend for
reduced renal perfusion, in the context of maintained renal
artery bulk flow and increased kidney volume, in agreement
with a reduced normalised renal blood flow (Fig. S5).
Of the 60 patients with CC, six were on beta-blockers, with
this sub-group showing a significant reduction in splenic artery
CSA, mean velocity and flux, spleen perfusion and portal vein
mean velocity, thus increasing the CC cohort group variance in
these measures. In addition, the DC sample size is currently
underpowered to determine significant incremental changes,
except in T1 relaxometry measures; this remains a work in
progress.
The significant difference in baseline MRI parameters in
those patients at risk of clinical events, within an average
follow-up period of three years and maximum follow-up of
seven years, is very encouraging. In this study 18% (11) of
patients had a negative clinical outcome, this is a similar sample
size to a recent study of events using multiparametric MRI of
the liver alone and an associated liver inflammation and fibrosis
score in which 10 patients (11%) were studied.26 In the current
study, we had more liver-related outcomes compared with pre-
vious studies (4% in a transient elastography study27 and 13% in
an ELF study28). The increased liver T1 (a marker of structural
severity) and reduced liver perfusion (a marker of haemody-
namic severity) in patients with early compensated liver cirrho-
sis experiencing future liver-related clinical outcomes has
biological plausibility and provides a link between surrogate
bio-imaging signals and robust clinical end points. The rele-
vance of the strong relationship of renal cortex T1 to both dis-
ease severity and clinical outcomes is novel. Two studies, in
patients with cirrhosis, have suggested changes in T1 occur
within the cortex of the kidney, but until now these studies
have been based on signal intensity changes of T1-weighted
images,29,30 with no quantitative measures of T1 relaxation
times having previously being reported. These previous studies
suggest that the mechanism and physiology of reduced renal
cortex T1 is decreased water content in the renal cortex due to
renal hypoperfusion. Whilst the overall blood flow to the kid-
neys was maintained in our study, there was both a trend
toward reduced renal perfusion, reduced renal artery flow per
beat decreased and kidney volume increased (Fig. 3), with a sig-1022 Journal of Hepatology 20nificant reduction in normalised bulk renal blood between HVs
and patients with CC (Fig. S5). Thus, it is intriguing to speculate
that regional vasoconstriction, driven by neurohormonal mech-
anisms, accounted for differential water content and reduced T1.
If this is proven to be the case, this has direct implications for
the treatment of hepatorenal syndrome.
The overall picture that emerges from this study is consistent
with our current understanding of the hyperdynamic circulation
and the peripheral arterial vasodilatation hypothesis.4 With
advancing liver disease, reflected by structural changes withinpredicted rise in portal pressure (calculated from MRI data as
a surrogate measure of HVPG20 shown in Fig. S6). Pooling of
blood in the splanchnic circulation as evidenced by increased
SMA bulk flow and splenic artery bulk flow (Fig. 2) perpetuates
this raised portal pressure. To accommodate the reduced effec-
tive central volume, the cardiac index increases in association
with a raised heart rate (Fig. 4). Importantly this compensatory
mechanism may be fragile as highlighted by the reduced LV
wall mass in DC in our study and by others.31 The DC group,
albeit small in number, were ambulatory in our study. It is plau-Recently, it has been proposed that vasodilation occurs in a dif-
ferential manner in regional beds. Using PC-MRI angiography,
McAvoy and colleagues32 found a reduction in total renal blood
flow in patients with advanced liver disease compared to HVs
but an increase in total hepatic blood flow and SMA flow. OurHere we present validation of our MRI measures against the
gold standard, showing the correlation of T1 with the continu-
ous biopsy variable of visual morphometry in METAVIR fibrosis
stage F4, in agreement with previous reports in the literature
across a wider range of fibrosis scores obtained from histol-
ogy.17,19 Further, we show that liver perfusion assessed in this
CC cohort shows a significant correlation with indocyanine
green (ICG-PDR and ICGR15). A recent study33 assessed ICG con-
tinuous clearance and HVPGmeasurement against 2D PC-MRI of
portal venous and hepatic arterial flow. They were able to
demonstrate useful correlates that suggest that further develop-We acknowledge ICG-PDR and ICGR15 are surrogates and not
true measures of perfusion. Formal ICG clearance would be
the optimal method, but this requires invasive transjugular hep-
atic venous sampling and simultaneous peripheral arterial sam-
pling in patients receiving a continuous peripheral ICG infusion,disease,34,35 and has the advantage of being widely available.
However, disadvantages include intra- and inter-observer vari-
ation, with reported intra-class variation of 0.4936 due to inad-
equate standardisation of protocols including anatomical site,nificant difference between HV and cirrhotics not reflected in
doppler ultrasound.34 Doppler ultrasound has been shown to
underestimate blood flow and be less reproducible in compar-
ison to PC-MRI,37 here we have shown the CoV of PC-MRI to
be less than 5% in HVs,38 further MRI has been shown to be
more reliable with respect to inter-observer variability than18 vol. 69 j 1015–1024
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OF HEPATOLOGYduplex doppler ultrasound.39 Several studies have used com-
puted tomography to assess portal vein and hepatic artery blood
flow, but this is limited by ionising radiation exposure.40
There are a number of clinical implications of this study.
Firstly, understanding the benefit vs. risk of existing and emerg-
ing therapeutics. Beta-blockers are used as standard care in the
setting of portal hypertension. However, non-selective beta-
blockers may be potentially deleterious after a critical threshold
or window period has been traversed. It remains unclear when
exactly this occurs, but this is likely to be related to diminishing
cardiac output and a reduction in renal blood flow.6 The concept
of using MR protocols to assess response to beta-blockers has
been explored by the Edinburgh group. They used PC-MRI to
show a significant reduction in cardiac output (as measured
by superior aorta blood flow) but maintenance of blood flow
in other vessels (SMA, portal vein, hepatic artery, azygous vein)
four weeks after commencing beta-blocker therapy, though this
was in a small cohort of patients who were heart rate respon-
ders (n = 9).13 Furthermore, using MRI protocols to assess novel
drug compounds has been highlighted by the recent report of
serelaxin providing therapeutic potential in renal dysfunction
in cirrhosis. In this study selective renal vasodilation did not
appear to be offset by a reduction in systemic blood pressure
or hepatic perfusion.41 Taken together with our findings, the
vision should be to use MRI protocols to assess response at an
individual level and thus provide tailored therapy which is
effective and safe. A further potential application for this MRI
protocol could be as a prognostic tool for overall liver outcomes
or specific complications. There is a growing body of literature
showing the promise of non-invasive markers of liver fibrosis
for prognostic performance.42,43 The ability of two simple scores
FIB4 and APRI to differentiate outcomes in early CC, as repro-
duced in this study (Fig. 5) cautions against positioning MRI
as a generic prognostic tool. However, the difference in param-
eters between patients with/without significant clinical out-
comes suggests that there is potential to use these parameters
for prediction, which would be an understandable ambition in
the era of emerging anti-fibrotic compounds. Larger studies
are required to determine clinical utility of these promising
multiparametric measures related to liver-related outcomes.44
This study was designed as a proof of concept study to assess
the feasibility of using MRI to assess different organs in cirrhosis
and confirms this is possible. Importantly, the scan time for the
present protocol is one hour. Whilst we have obviated the
requirement for an intravenous contrast agent, the scan time
can now be reduced by omitting parameters which have been
found to be non-contributory. This will be important for patient
compliance and reducing cost and burden on radiology service
provision time for future implementation into clinical practice.
Whilst the MR picture obtained provides an overview it is by
no means an exclusive assessment of the hyperdynamic circula-
tion. For example, the current protocol does not provide an
assessment of systemic vascular resistance nor does it delineate
intrahepatic shunts, which we have postulated to underpin the
marked reduction in liver perfusion. We deliberately chose
aspects of MRI measurements that have been validated previ-
ously by our group and others based on comparison to gold
standard reference tests including invasive angiography and
liver biopsy. The current imaging protocol has been performed
on 1.5 T but can easily be applied at 3 T, which provides higher
signal-to-noise ratio and spatial resolution. Demonstrating that
monitoring of therapy with MRI protocols can change hard
Journal of Hepatology 20clinical outcomes and is cost effective within a multicentred
randomised controlled trial will be required before considering
implementation into clinical care.
We have shown that quantitative MRI can provide a global
picture of cirrhosis by measuring aspects of flow, volume, com-
position and perfusion in critical organs. The change of key
parameters including liver T1, liver perfusion and renal cortical
T1 in both progressive disease and in liver-related clinical out-
comes has tangible utility in the understanding and treatment
of the complications of chronic liver disease.
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